Candidate Oligo Therapeutic Target, miR-330-3p, Induces Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells via HDAC4

Figure 5

miR-330-3p reduced the expression of HDAC4 by targeting the 3′-UTR region of HDAC4 mRNA. (a, b) Both RNA and protein expression levels were dysregulated in tamoxifen-resistant breast cancer cell lines. (c) Potential binding sites of miR-330-3p on HDAC4-mRNA. (d) Dual-luciferase reporter assay confirmed the binding sites of miR-330-3p on HDAC4-mRNA. (e) miR-330-3p could regulate HDAC4 mRNA expression directly. (f) Inconsistency with RNA level and miR-330-3p regulated HDAC4 protein expression (data are represented as mean ± S.D of triplicate experiments;  < 0.05).

(a)

(b)

(c)

(d)

(e)

(f)